1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited

BOT.AX
Botanix Pharmaceuticals LimitedAU flagAustralian Securities Exchange
0.03
AUD
+0.00
- -
49.81MMarket Cap
Botanix Pharmaceuticals Limited
BOT.AX
(Australian Securities Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-3.14
-2.26
-1.48
-0.43
-0.03
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
- -
-0.01
-0.01
-0.01
-0.05
Basic EPS, GAAP
-1.36
-1.03
-1.06
-0.24
-0.03
-0.01
- -
-0.01
- -
- -
- -
- -
- -
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.98
-4.29
-2.81
-0.74
0.01
-0.01
0.02
0.01
0.03
- -
0.02
0.02
- -
0.01
0.06
0.03
Book Value per Share
-3.03
-3.32
-2.21
-0.58
0.05
0.01
0.02
0.01
0.03
- -
0.03
0.02
- -
0.01
0.05
0.03
Tangible Book Value per Share
1
1
1
4
41
86
158
434
488
760
936
973
976
1,154
1,502
1,845
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
6
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12,431.05
-2,568.82
-1,499.72
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
Depreciation Expense
-2
-2
-2
-2
-1
-1
-2
-5
-11
-17
-17
-3
-13
-9
-14
-86
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8,893.05
-2,304.63
-1,500.65
Profit Margin (%)
-3
-1
-3
-3
2
1
3
5
16
- -
23
21
7
12
79
75
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23
LT Debt
- -
-2
-2
-3
2
1
3
5
16
1
24
21
8
23
109
81
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-117.01
-105.09
- -
- -
-18.01
-127.96
-90.3
-24.31
-117.83
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
453.24%
91.45%
-25.23%
Free Cash Flow
- -
7,059.13%
-94.17%
Net Income, GAAP
119.03%
151.78%
522.91%
Sales/Revenue/Turnover
- -
- -
856.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
6

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.05

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Bioneer Corporation (064550.KQ)
GNI Group Ltd. (2160.T)
PreveCeutical Medical Inc. (PRVCF)
Egetis Therapeutics AB (publ) (EGTX.ST)
ContraFect Corp. (CFRXQ)
Vincerx Pharma, Inc. (VINC)
Business
Botanix Pharmaceuticals Limited (ASX: BOT) is a clinical-stage dermatology company developing and commercializing antimicrobial skin products based on its proprietary patented cannabidiol (CBD) platform technology. The company offers a pipeline of product candidates including BTX 170, a non-antibiotic treatment for serious skin infections such as atopic dermatitis and hidradenitis suppurativa; Sofdra, a cannabidiol cream for the treatment of primary axillary hyperhidrosis; and additional formulations targeting acne vulgaris, psoriasis, and other inflammatory skin diseases. Botanix manufactures and sells pharmaceutical products focused on dermatological applications, with operations primarily in Australia and the United States. Founded in 2014 and headquartered in Sydney, Australia, the company targets the global dermatology market, serving patients with inflammatory and infectious skin conditions through partnerships with contract manufacturers and clinical trial networks across North America and Europe. Its business segments encompass research and development, clinical trials, regulatory approvals, and commercialization of CBD-based topical therapies. In the last two years, Botanix has advanced its pipeline with positive Phase 3 trial results for Sofdra in 2024, leading to a New Drug Application submission to the U.S. FDA in early 2025; formed a strategic manufacturing alliance with a leading U.S. contract development organization for commercial-scale production; and completed a A$50 million capital raise in late 2024 to fund Phase 2 trials for BTX 170 and market expansion into Europe. The company also acquired complementary IP assets in antimicrobial peptides in mid-2025, enhancing its non-antibiotic platform, and announced leadership expansions to support U.S. commercialization efforts. These developments position Botanix for potential revenue generation from Sofdra approval expected in 2026.

Company News

APIChatGPT